News & Updates
Showing Multidisciplinary articles
Showing

Intranasal neuroEPO slows Alzheimer’s progression
An intranasally administered recombinant human erythropoietin without erythropoietic activity and shorter plasma half-life (neuroEPO) restores cognitive function or delays progression in most patients with mild-to-moderate Alzheimer’s disease, results of the phase II/III double-blind, placebo-controlled ATHENEA trial have shown.
Intranasal neuroEPO slows Alzheimer’s progression
04 Jan 2024
Multiple myeloma quadruplet prolongs survival, induces deeper responses
Adding subcutaneous daratumumab to the three-drug regimen containing bortezomib, lenalidomide, and dexamethasone (VRd) appears to improve outcomes for transplant-eligible patients with newly diagnosed multiple myeloma (MM), with extended disease-free periods and increased depth of response, according to the phase III PERSEUS trial.







